These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 6297208)

  • 1. Trilostane in the management of Cushing's syndrome.
    Semple CG; Beastall GH; Gray CE; Thomson JA
    Acta Endocrinol (Copenh); 1983 Jan; 102(1):107-10. PubMed ID: 6297208
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Concomitant falls of plasma cortisol and ACTH levels in a case of Cushing's disease during treatment with trilostane.
    Nomura K; Demura H; Imaki T; Miyagawa M; Ono M; Yano T; Shizume K
    Acta Endocrinol (Copenh); 1984 Jan; 105(1):93-8. PubMed ID: 6320567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Experience with trilostane in the treatment of Cushing's syndrome.
    Dewis P; Anderson DC; Bu'lock DE; Earnshaw R; Kelly WF
    Clin Endocrinol (Oxf); 1983 Jun; 18(6):533-40. PubMed ID: 6883729
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment of Cushing's syndrome with trilostane (WIN 24,540), an inhibitor of adrenal steroid biosynthesis.
    Komanicky P; Spark RF; Melby JC
    J Clin Endocrinol Metab; 1978 Nov; 47(5):1042-51. PubMed ID: 233687
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trilostane for Cushing's syndrome.
    Med Lett Drugs Ther; 1985 Oct; 27(698):87-8. PubMed ID: 4046969
    [No Abstract]   [Full Text] [Related]  

  • 6. Efficacy of trilostane for the treatment of equine Cushing's syndrome.
    McGowan CM; Neiger R
    Equine Vet J; 2003 Jun; 35(4):414-8. PubMed ID: 12880011
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term efficacy of trilostane for Cushing's syndrome due to adrenocorticotropin-independent bilateral macronodular adrenocortical hyperplasia.
    Obata Y; Yamada Y; Baden MY; Hosokawa Y; Saisho K; Tamba S; Yamamoto K; Matsuzawa Y
    Intern Med; 2011; 50(21):2621-5. PubMed ID: 22041369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Effect of a 3 beta-hydroxysteroid dehydrogenase inhibitor (trilostane) on Cushing's syndrome].
    Nakada T; Ishikawa S; Koike H; Kazama T; Katayama T
    Nihon Hinyokika Gakkai Zasshi; 1985 Jan; 76(1):110-5. PubMed ID: 3859681
    [No Abstract]   [Full Text] [Related]  

  • 9. Trilostane-induced inhibition of cortisol secretion results in reduced negative feedback at the hypothalamic-pituitary axis.
    Teshima T; Hara Y; Takekoshi S; Nezu Y; Harada Y; Yogo T; Teramoto A; Osamura RY; Tagawa M
    Domest Anim Endocrinol; 2009 Jan; 36(1):32-44. PubMed ID: 19041802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Corticotropin releasing hormone stimulation test: diagnostic aspects in Cushing's syndrome.
    Boscaro M; Rampazzo A; Sonino N; Merola G; Scanarini M; Mantero F
    J Endocrinol Invest; 1987 Jun; 10(3):297-302. PubMed ID: 3040851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Atypical Cushing's syndrome in a dog. A case report].
    Hoffrogge S; Fels L; Schmicke M; Mischke R
    Tierarztl Prax Ausg K Kleintiere Heimtiere; 2017 Jun; 45(3):186-192. PubMed ID: 28447709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Clinical usefulness of pharmacological treatment of Cushing's syndrome].
    Saito J; Nishikawa T
    Nihon Rinsho; 1994 Mar; 52(3):793-6. PubMed ID: 8164384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of Cushing's syndrome in dogs.
    McLean CL
    Vet Rec; 2009 Oct; 165(17):512. PubMed ID: 19855117
    [No Abstract]   [Full Text] [Related]  

  • 14. [Trilostane therapy in patients with hypercorticism].
    Saito Z; Ando A; Hashiba T; Mikeo T; Takeda J
    Horumon To Rinsho; 1984 Jan; 32(1):53-8. PubMed ID: 6585278
    [No Abstract]   [Full Text] [Related]  

  • 15. Serum insulin concentrations in horses with equine Cushing's syndrome: response to a cortisol inhibitor and prognostic value.
    McGowan CM; Frost R; Pfeiffer DU; Neiger R
    Equine Vet J; 2004 Apr; 36(3):295-8. PubMed ID: 15147141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Different therapeutic efficacy of ketoconazole in patients with Cushing's syndrome.
    Engelhardt D; Jacob K; Doerr HG
    Klin Wochenschr; 1989 Feb; 67(4):241-7. PubMed ID: 2538676
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ATR-101, a selective ACAT1 inhibitor, decreases ACTH-stimulated cortisol concentrations in dogs with naturally occurring Cushing's syndrome.
    Langlois DK; Fritz MC; Schall WD; Bari Olivier N; Smedley RC; Pearson PG; Bailie MB; Hunt SW
    BMC Endocr Disord; 2018 May; 18(1):24. PubMed ID: 29720169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Corticotropin-dependent Cushing's syndrome in older people: presentation of five cases and therapeutical use of ketoconazole.
    Berwaerts JJ; Verhelst JA; Verhaert GC; Verhaegen AA; Abs RE
    J Am Geriatr Soc; 1998 Jul; 46(7):880-4. PubMed ID: 9670876
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of bromocriptine in pituitary-dependent Cushing's syndrome.
    Lamberts SW; Birkenhäger JC
    J Endocrinol; 1976 Aug; 70(2):315-6. PubMed ID: 184231
    [No Abstract]   [Full Text] [Related]  

  • 20. Evaluation of baseline cortisol, endogenous ACTH, and cortisol/ACTH ratio to monitor trilostane treatment in dogs with pituitary-dependent hypercortisolism.
    Burkhardt WA; Boretti FS; Reusch CE; Sieber-Ruckstuhl NS
    J Vet Intern Med; 2013; 27(4):919-23. PubMed ID: 23701195
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.